Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.

British journal of clinical pharmacology - 1 Jun 2018

Gong Jiachang, Iacono Lisa, Iyer Ramaswamy A, Humphreys William G, Zheng Ming

Abstract excerpt

AIMS: Previous studies demonstrated direct correlation between CYP2C19 genotype and BMS-823778 clearance in healthy volunteers. The objective of the present study was to develop a physiologically-based pharmacokinetic (PBPK) model for BMS-823778 and use the model to predict PK and drug-drug interaction (DDI) in virtual populations with multiple polymorphic genes. METHODS: The PBPK model was built and verified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP3A Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Glucuronosyltransferase

Share to Itraconazole

Share to Pharmacogenomic Variants

Share to Pyridines

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 29469197
DOI: 10.1111/bcp.13565
PMCID: PMC5980543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.PMID 29469197Read ↗

Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study .Semantic proximity Read ↗

Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.Semantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.Semantic proximity Read ↗

Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.Semantic proximity Read ↗

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects.Semantic proximity Read ↗

Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay.Semantic proximity Read ↗

Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.Semantic proximity Read ↗

Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications.Semantic proximity Read ↗

A physiologically-based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: an evaluation of CYP2C19 activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.